NewEdge Advisors’s Applied Therapeutics APLT Stock Holding History

NewEdge Advisors’s Portfolio APLT Stock Details APLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-199	Closed	-$929	–	3814
2024 Q2	$929	Buy	+199	New	+$942	﹤0.01%	3481

Other funds holding APLT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

NewEdge Advisors's APLT Position: Q3 2024 in Review

NewEdge Advisors sold out of Applied Therapeutics (APLT) in Q3 2024, closing a stake of 199 shares — an estimated $929 sold.

NewEdge Advisors first reported a position in APLT in Q2 2024 and held it in 1 quarter. The position peaked at $929 in Q2 2024. 126 funds tracked by Wall St. Rank hold APLT as of Q3 2024.

NewEdge Advisors reported no remaining Applied Therapeutics position as of Q3 2024 after selling out during the quarter.
NewEdge Advisors sold 199 Applied Therapeutics shares in Q3 2024, an estimated $929.
NewEdge Advisors first reported a position in Applied Therapeutics in Q2 2024 and held it in 1 quarter.
NewEdge Advisors's Applied Therapeutics position peaked at $929 in Q2 2024.
126 funds tracked by Wall St. Rank held Applied Therapeutics as of Q3 2024.

Based on NewEdge Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.